0.425
-0.05 (-10.95%)
| Previous Close | 0.478 |
| Open | 0.493 |
| Volume | 258,323 |
| Avg. Volume (3M) | 802,124 |
| Market Cap | 14,628,883 |
| Price / Sales | 0.030 |
| Price / Book | 0.120 |
| 52 Weeks Range | |
| Earnings Date | 9 Feb 2026 |
| Profit Margin | -18.21% |
| Operating Margin (TTM) | -7.62% |
| Diluted EPS (TTM) | -3.12 |
| Quarterly Revenue Growth (YOY) | 4.40% |
| Total Debt/Equity (MRQ) | 286.38% |
| Current Ratio (MRQ) | 1.50 |
| Operating Cash Flow (TTM) | -34.49 M |
| Levered Free Cash Flow (TTM) | -11.40 M |
| Return on Assets (TTM) | -2.31% |
| Return on Equity (TTM) | -47.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | Inotiv, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 11.31% |
| % Held by Institutions | 23.66% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Massar Capital Management, Lp | 30 Sep 2025 | 350,000 |
| Vantage Point Financial Llc | 31 Dec 2025 | 336,546 |
| Acorn Creek Capital Llc | 31 Dec 2025 | 158,750 |
| Mount Lucas Management Lp | 30 Sep 2025 | 143,500 |
| 52 Weeks Range | ||
| Median | 3.00 (605.38%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Lake Street | 04 Dec 2025 | 3.00 (605.38%) | Buy | 0.880 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Jan 2026 | Announcement | Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery |
| 11 Dec 2025 | Announcement | Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities |
| 03 Dec 2025 | Announcement | Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update |
| 25 Nov 2025 | Announcement | Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™ |
| 21 Nov 2025 | Announcement | Inotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025 |
| 17 Nov 2025 | Announcement | Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |